Ligand Pharmaceuticals stock hits 52-week high at $183.98

Published 06/10/2025, 16:48
Ligand Pharmaceuticals stock hits 52-week high at $183.98

Ligand Pharmaceuticals Incorporated stock reached a 52-week high of $183.98, marking a significant milestone for the company. According to InvestingPro data, the company maintains strong financials with a current ratio of 5.45 and impressive revenue growth of 40.54% in the last twelve months. Over the past year, Ligand Pharmaceuticals has experienced a remarkable 78.08% increase in its stock value, reflecting strong investor confidence and positive market performance. This achievement underscores the company’s successful strategies and growth potential in the pharmaceutical sector. As Ligand continues to innovate and expand its portfolio, investors remain optimistic about its future prospects, with analysts setting a high target of $206. InvestingPro analysis suggests the stock is currently trading above its Fair Value, with 12 additional exclusive insights available to subscribers through the comprehensive Pro Research Report.

In other recent news, Ligand Pharmaceuticals has been the focus of several analyst upgrades and financial activities. The company recently completed a $460 million convertible notes offering, which included a full exercise of an option to purchase an additional $60 million in notes, resulting in net proceeds of approximately $445.1 million. This capital raise was followed by Oppenheimer increasing its price target for Ligand Pharma to $190, citing the lower weighted average cost of capital (WACC) from the capital raise. Benchmark also raised its price target to $175, attributing the increase to Ligand’s strong second-quarter 2025 earnings report. Additionally, H.C. Wainwright increased its price target to $206, following the FDA’s approval of an update to the REMS labeling for FILSPARI, which included changes to liver function and pregnancy monitoring requirements. These recent developments reflect significant financial maneuvers and positive analyst sentiment for Ligand Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.